Retatrutide
The Triple-Agonist Peptide Rewriting Metabolic Science
First-in-class GLP-1/GIP/Glucagon receptor agonist · Phase 3 clinical trials · Record-setting metabolic efficacy
Last updated: February 2026
At a Glance
IN THIS ARTICLE
Why Retatrutide Matters Right Now
In December 2025, Eli Lilly announced that retatrutide delivered an average weight loss of 71.2 pounds (28.7%) in the TRIUMPH-4 Phase 3 trial — the most dramatic single-agent result in the history of metabolic medicine. Seven additional Phase 3 readouts are expected throughout 2026, making retatrutide arguably the most closely-watched investigational compound in the world right now.
What makes retatrutide fundamentally different from semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound) is its third receptor target: glucagon. While predecessors act on one or two incretin pathways, retatrutide simultaneously engages three metabolic signaling systems that evolved over millions of years to regulate energy balance, appetite, and fat storage.
The trajectory is striking: first-generation GLP-1 agonists (liraglutide) produced ~8% weight reduction. Second-generation (semaglutide) achieved ~17%. Dual-agonists (tirzepatide) reached ~22.5%. Triple-agonists (retatrutide) have now crossed 28%. Each added receptor target creates synergistic interactions that amplify therapeutic effect beyond what any single pathway can deliver.
GlobalData forecasts retatrutide sales reaching $15.6 billion by 2031, and Lilly's existing GLP-1 franchise (Zepbound alone generated $3.6 billion in Q3 2025) suggests the market has enormous appetite for next-generation metabolic therapies.
Mechanism of Action: Three Receptors, One Molecule
Retatrutide is a single 39-amino acid synthetic peptide engineered to simultaneously activate three distinct metabolic receptors. Each receptor triggers different — but complementary — physiological responses:
Triple Receptor Activation
| Receptor | Natural Hormone | Primary Effects | Retatrutide Potency |
|---|---|---|---|
| GLP-1R | Glucagon-like Peptide-1 | Appetite suppression, delayed gastric emptying, insulin secretion, cardiovascular protection | Lower than native GLP-1 |
| GIPR | Glucose-dependent Insulinotropic Polypeptide | Insulin sensitization, fat metabolism, lipid clearance, bone preservation | Higher than native GIP |
| GCGR | Glucagon | Thermogenic energy expenditure, hepatic fat oxidation, lipolysis, glycogen mobilization | Lower than native glucagon |
The glucagon receptor component is what truly differentiates retatrutide. While pure GLP-1 agonists primarily reduce food intake (the 'eat less' pathway), glucagon activation adds a 'burn more' pathway — directly increasing resting energy expenditure and driving hepatic fat oxidation. This is why retatrutide produced results in liver fat reduction that neither semaglutide nor tirzepatide could match at comparable timepoints.
The C20 fatty diacid moiety attached to the peptide backbone enables tight binding to serum albumin, extending the plasma half-life to support once-weekly dosing. Retatrutide is more potent at the human GIP receptor than the natural hormone itself, while exhibiting calibrated, lower-than-natural activity at GLP-1 and glucagon receptors — a deliberate design choice to balance efficacy against side effects.
At the cellular level, receptor binding triggers G-protein-coupled signaling cascades: GLP-1R and GIPR activation elevates intracellular cAMP via Gαs coupling, stimulating insulin secretion and suppressing glucagon release in a glucose-dependent manner. GCGR activation in hepatocytes promotes glycogenolysis, gluconeogenesis, and critically, mitochondrial fatty acid β-oxidation — the mechanism behind its liver fat-clearing ability.
Clinical Trial Data: The TRIUMPH Program
Retatrutide's clinical development is built around the TRIUMPH program — a comprehensive suite of Phase 3 trials evaluating the compound across multiple metabolic conditions simultaneously using an innovative 'basket trial' design.
TRIUMPH Clinical Trial Program
| Trial | Population | Endpoints | Status |
|---|---|---|---|
| TRIUMPH-1 | Obesity/overweight + OSA and/or OA basket | Weight management + complication resolution | Ongoing — 2026 readout |
| TRIUMPH-2 | Obesity/overweight + OSA and/or OA basket | Weight management + complication resolution | Ongoing — 2026 readout |
| TRIUMPH-3 | Obesity/overweight + cardiovascular disease | Weight + CV outcomes | Ongoing — 2026 readout |
| TRIUMPH-4 | Obesity/overweight + knee osteoarthritis | Weight + pain + physical function | Completed — Dec 2025 ✓ |
| Phase 3 T2D | Type 2 diabetes | HbA1c + weight reduction | Ongoing — 2026 readout |
| Phase 3 MASLD | Metabolic liver disease (fatty liver) | Liver fat + fibrosis | Ongoing — 2026 readout |
| Phase 3 Chronic Low Back Pain | Obesity + chronic back pain | Pain + weight + function | Ongoing — 2026 readout |
| Phase 3 Maintenance | Maintenance dosing (4mg) | Weight maintenance post-loss | Ongoing — 2026 readout |
Key Results to Date
Phase 2 (NEJM, 2023)
24.2% mean body weight reduction at 48 weeks with the 12mg dose — the highest single-agent weight loss ever reported in a randomized controlled trial at that time. 338 participants across 7 dose groups vs. placebo.
TRIUMPH-4 (Dec 2025)
28.7% weight loss (71.2 lbs average) at 68 weeks with 12mg dose. Pain reduction of 4.5 points on WOMAC scale. 14.1% of patients on 9mg were completely free of knee pain. Systolic blood pressure reduced by 14.0 mmHg. Significant reductions in non-HDL cholesterol, triglycerides, and hs-CRP.
Meta-analysis (2025)
Pooled analysis of 878 patients across 3 RCTs showed significant reductions in body weight (−14.33%), BMI (−5.38), waist circumference (−10.51 cm), and fasting plasma glucose.
Retatrutide vs. Semaglutide vs. Tirzepatide
The evolution from single to dual to triple agonism follows a pattern: each added receptor creates synergistic metabolic effects. Semaglutide proved the GLP-1 concept. Tirzepatide showed that adding GIP amplifies it. Retatrutide demonstrates that glucagon adds a fundamentally new dimension — thermogenesis and hepatic fat clearance — that the incretin-only approach cannot replicate.
Importantly, retatrutide's advantage is not simply 'more weight loss.' The glucagon-driven increase in energy expenditure means a larger proportion of weight lost comes from fat (rather than lean mass), and the hepatic effects suggest particular promise for metabolic dysfunction-associated steatotic liver disease (MASLD/NASH), for which no approved pharmaceutical treatment currently exists.
| Property | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor Targets | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Generation | 2nd gen single-agonist | 1st gen dual-agonist | 1st gen triple-agonist |
| Max Weight Loss | ~16.9% (STEP trials) | ~22.5% (SURMOUNT) | ~28.7% (TRIUMPH-4) |
| Dosing | Once weekly SC | Once weekly SC | Once weekly SC |
| Thermogenesis | Minimal | Moderate (via GIP) | Significant (via glucagon) |
| Liver Fat Effect | Moderate reduction | Strong reduction | Strongest (glucagon-driven) |
| CV Risk Markers | SELECT trial positive | SURPASS-CVOT ongoing | Significant BP/lipid reduction |
| FDA Status | Approved (2021) | Approved (2022) | Investigational (~2027) |
| Brand Names | Ozempic / Wegovy | Mounjaro / Zepbound | None yet |
| Manufacturer | Novo Nordisk | Eli Lilly | Eli Lilly |
Safety Profile and Considerations
The side effect profile of retatrutide is broadly consistent with other incretin-based therapies. Gastrointestinal events (nausea, diarrhea, vomiting, constipation) are the most commonly reported adverse effects, generally mild to moderate in severity, and tend to diminish with continued treatment. Importantly, GI side effects infrequently led to discontinuation in the TRIUMPH-4 trial.
The glucagon component introduces a theoretical concern: glucagon raises blood glucose. In practice, the simultaneous GLP-1 and GIP agonism appear to counterbalance this effect, maintaining or improving glycemic control even while activating glucagon receptors. However, this is an area where the ongoing TRIUMPH Type 2 Diabetes trial will provide critical data.
Because retatrutide remains investigational, long-term safety data (beyond 68 weeks) is not yet available. The seven Phase 3 readouts expected in 2026 will substantially expand the safety database across diverse patient populations, including those with cardiovascular disease, sleep apnea, and liver disease.
Current Research Landscape
Retatrutide exists within an intensely competitive field. Beyond Lilly's own pipeline (which includes the oral GLP-1 orforglipron), Amgen's MariTide (a dual GLP-1R/GIPR antibody-peptide conjugate with monthly dosing), Viking Therapeutics' VK2735 (a dual GLP-1/GIP agonist), and Novo Nordisk's CagriSema (semaglutide + amylin analog) all represent next-generation approaches to metabolic intervention.
What distinguishes retatrutide is the glucagon component's unique contribution to energy expenditure and liver fat clearance. No other clinical-stage compound replicates this triple-agonist approach. If the TRIUMPH liver disease trial confirms the preclinical promise, retatrutide could become the first pharmacological treatment for MASLD/NASH — a condition affecting an estimated 30% of the global population.
For researchers, retatrutide represents a paradigm shift in understanding how multiple hormone systems can be simultaneously modulated by a single molecule. The triple-agonist design principle is likely to influence the next decade of metabolic drug development.
Frequently Asked Questions
What is retatrutide?
How does retatrutide differ from Ozempic or Mounjaro?
What are retatrutide's clinical trial results?
Is retatrutide FDA-approved?
What is retatrutide's molecular structure?
What conditions is retatrutide being studied for?
What are the side effects of retatrutide?
How much does retatrutide cost?
References
- [1] Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metab. 2022;34(9):1234-1247.
- [2] Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. NEJM. 2023;389:514-526.
- [3] Eli Lilly. TRIUMPH-4 Phase 3 Topline Results. Press Release, December 11, 2025.
- [4] Giblin K, et al. Retatrutide for the treatment of obesity, OSA and knee OA: TRIUMPH program design. Diabetes Obes Metab. 2026;28(1):83-93.
- [5] Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in T2D. Lancet. 2022;400:1869-1881.
- [6] GlobalData. Retatrutide Sales Forecast: $15.6B by 2031. December 2025.
